Agenus R&D update & Second Quarter Earnings Report
Agenus Inc. (NASDAQ: AGEN) announced it will update its pipeline and financial results for Q2 2020 on August 6, 2020. The video conference call will review key topics including registration strategies for balstilimab and zalifrelimab, progress with Betta Pharmaceuticals in China, and the clinical advancement of AGEN1181. Additionally, the company will discuss breakthroughs in allogeneic iNKT cells for COVID-19 and cancer, along with updates on AGEN1223 and AGEN2373. The financial results will provide insight into the company’s fiscal health and future outlook.
- Upcoming release of Q2 2020 financial results expected to provide clarity on company's fiscal health.
- Discussion on partnership progress with Betta Pharmaceuticals may highlight international growth opportunities.
- Potential breakthroughs in COVID-19 and cancer therapies could position Agenus favorably in competitive markets.
- None.
LEXINGTON, Mass., July 29, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it will provide an update on programs and plans and release its second quarter 2020 financial results before the market opens on Thursday, August 6, 2020. Agenus executives and thought leaders will host a video conference call and webcast at 8:30 a.m. ET.
Topics to be discussed:
- Registration plans and strategy for balstilimab +/- zalifrelimab
- Agenus & Betta Pharmaceuticals partnership progress for China
- Clinical status/next steps for AGEN1181 (NextGen CTLA-4) +/- balstilimab (anti-PD-1)
- Allogeneic iNKT cells potential breakthrough for COVID-19 and cancer based on efficacy and cost
- Cell therapy and antibody combinations preclinically show curative potential
- AGEN1223 & AGEN2373 clinical update and plans for bali +/- zali combos
- Myeloid immune response modifiers (TIGIT bispecific & other novel targets)
Live Call: Dial 1-844-492-3727 (U.S.) or 1-412-317-5118 (International)
Webcast: The call will be accessible from the Company's website at http://investor.agenusbio.com/presentation-webcasts or via https://www.webcaster4.com/Webcast/Page/1556/35715. A replay will be available approximately two hours after the call and will remain available until November 7, 2020.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio.
Contact
Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/agenus-rd-update--second-quarter-earnings-report-301102427.html
SOURCE Agenus Inc.
FAQ
What date will Agenus announce its Q2 2020 financial results?
What key topics will be discussed in the Agenus conference call?
How can I access the Agenus Q2 2020 earnings call?
What is the focus of Agenus as an immuno-oncology company?
